69284 NovaBlue(DE3) Competent Cells - Novagen

69284
View Pricing & Availability

Overview

Replacement Information

Pricing & Availability

Catalogue Number AvailabilityPackaging Qty/Pack Price Quantity
69284-3CN
Retrieving availability...
Limited AvailabilityLimited Availability
In Stock 
Discontinued
Limited Quantities Available
Availability to be confirmed
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      Contact Customer Service

      Plastic ampoule 0.4 ml
      Retrieving price...
      Price could not be retrieved
      Minimum Quantity needs to be mulitiple of
      Upon Order Completion More Information
      You Saved ()
       
      Request Pricing
      Description
      OverviewNovaBlue(DE3) Competent Cells is a K-12 strain with high transformation efficiency and recA endA mutations. The DE3 lysogen of NovaBlue is potentially useful as a stringent host due to the presence of the lacIq repressor encoded by the F episome. 

      This product is covered under license from Brookhaven National Labs. Commercial entities need to obtain a research use license prior to purchase. Please contact your licensing department to confirm that your company already holds a research use license.
      This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges MilliporeSigma to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.




      This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the 'EMD Product') requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
      Catalogue Number69284
      Brand Family Novagen®
      References
      Product Information
      Components
      Guaranteed efficiencyGuaranteed efficiency: > 1 x 10⁸ cfu/μg
      Quality LevelMQ100
      Applications
      Biological Information
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Dry Ice Only
      Toxicity Multiple Toxicity Values, refer to MSDS
      Storage ≤ -70°C
      Avoid freeze/thaw Avoid freeze/thaw
      Do not freeze Ok to freeze
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications

      Documentation

      NovaBlue(DE3) Competent Cells - Novagen SDS

      Title

      Safety Data Sheet (SDS) 

      NovaBlue(DE3) Competent Cells - Novagen Certificates of Analysis

      TitleLot Number
      69284

      Citations

      Title
    • Mark S. McClain and Timothy L. Cover. (2007) Functional analysis of neutralizing antibodies against Clostridium perfringens epsilon-toxin. Infection and Immunity 75, 1785-1793.
    • Yuichi Hongoh, et al. (2006) Phylogenetic diversity, localization, and cell morphologies of members of the candidate phylum TG3 and a subphylum in the phylum Fibrobacteres, recently discovered bacterial groups dominant in termite guts. Applied and Enviornmental Microbiology 72, 6780-6788.
    • Ryan Simkovsky and Jonathan King. (2006) An elongated spine of buried core residues necessary for in vivo folding of the parallel β-helix of P22 tailspike adhesin. Proceedings of the National Academy of Sciences (USA) 103, 3575-3580.
    • Steven D. Breazeale, et al. (2005) A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-Amino-4-deoxy-L-arabinose. Identification and function of UDP-4-deoxy-4-formamido-L-arabinose. Journal of Biological Chemistry 280, 14154-14167.
    • Dale K. Shumaker, et al. (2005) Functions and dysfunctions of the nuclear lamin Ig-fold domain in nuclear assembly, growth, and Emery-Dreifuss muscular dystrophy. Proceedings of the National Academy of Sciences (USA) 102, 15494-15499.
    • John V. McDowell, et al. (2004) Demonstration of the involvement of outer surface protein E coiled coil structural domains and higher order structural elements in the binding of infection-induced antibody and the complement-regulatory protein, factor H. Journal of Immunology 173, 7471-7480.
    • An X. Tran, et al. (2004) Periplasmic cleavage and modification of the 1-phosphate group of Helicobacter pylori lipid A. Journal of Biological Chemistry 279, 55780-55791.
    • Jae Hyung Koo, Ick Hyun Cho and Yu Sam Kim. (2000) The malonate decarboxylase operon of Acinetobacter calcoaceticus KCCM 40902 is regulated by malonate and the transcriptional repressor MdcY. Journal of Bacteriology 182, 6382-6390.
    • C. Hatfield, et al. (1997) Epitope mapping by recombination PCR mutagenesis. Bio/Techniques 22, 332-337.
    • K.D. Janda, et al. (1997) Selection for catalysis in combinatorial antibody libraries. Science 275, 945-948.